The ceRNA regulatory network, in which XIST can compete for endogenous miRNAs was confirmed in nasopharyngeal carcinoma, esophageal squamous cell carcinoma, gastric cancer, pancreatic cancer, prostate cancer, hepatocellular carcinoma, glioma, bladder cancer [14,19,21–23,37–40]. This evidence concerns the gene XIST and prostate cancer.